TL;DR
This study identifies hsa-miR-144-3p as a potential early biomarker for Parkinson's Disease (PD) by observing its consistent downregulation in the serum of drug-naïve PD patients. Further analysis suggests this microRNA plays a role in regulating coagulation, a process known to be disrupted in PD, opening avenues for early diagnosis and understanding disease mechanisms.
What Problem Does This Paper Address?
Parkinson's Disease (PD) is a complex neurodegenerative disorder where aging is a primary risk factor. While microRNAs (miRNAs) are known to be involved in aging processes and have emerged as potential biomarkers, their specific role in the interplay between aging and PD pathogenesis, particularly in the early stages of the disease, remains unclear. Existing studies often focus on advanced PD patients, whose miRNA profiles might be influenced by drug treatments or disease progression. This paper aims to bridge this gap by investigating miRNAs in drug-naïve PD patients within the context of aging, seeking to identify early diagnostic markers and understand their functional relevance.
Methods
The researchers employed a multi-stage approach:
- Next-Generation Sequencing (NGS): Serum samples from a discovery cohort (drug-naïve PD patients, healthy controls, and centenarians) were analyzed using NGS to profile miRNA expression.
- Differential Expression Analysis: Statistical methods (DESeq2) were used to identify miRNAs with significantly different expression levels between groups.
- Network Reconstruction (ARACNE): To understand miRNA interactions, the ARACNE algorithm was used to build miRNA co-expression networks. This was followed by community detection (Louvain algorithm) to identify groups of interacting miRNAs.
- Quantitative RT-PCR (qPCR): This is a standard validation technique used to confirm the expression levels of candidate miRNAs identified by NGS.
- Functional Analysis: Tools like MiRTarBase, HMDD3.2, and MIENTURNET were used to predict and analyze miRNA targets, their involvement in biological pathways (KEGG, Reactome), and their association with diseases.
Datasets
The study utilized serum samples from several cohorts:
- Discovery Cohort:
- Drug-naïve Parkinson's Disease (dnPD) patients (n=61)
- Healthy Controls (CTR) (n=77, split between GOE and UNIBO sites)
- Centenarians (CENT) (n=27)
- Validation Cohort:
- Advanced Parkinson's Disease (adPD) patients (n=12)
- Drug-naïve Parkinson's Disease (dnPD) patients (n=144)
- Parkinson's Disease siblings (PDsibs) (n=48)
- Healthy Controls (CTR) from the discovery cohort were used as a reference.
The NGS data has been deposited in the NCBI's Gene Expression Omnibus (GEO) under accession number GSE180193.
Key Insights and Ideas
- hsa-miR-144-3p as an Early PD Biomarker: The most significant finding is the consistent downregulation of hsa-miR-144-3p in early, drug-naïve PD patients. This suggests it could serve as an early indicator of the disease, potentially predating more overt symptoms or drug interventions.
- Coagulation Pathway Involvement: Functional analysis revealed that hsa-miR-144-3p is implicated in the regulation of the complement and coagulation cascades. This is particularly interesting because alterations in blood coagulation are increasingly recognized as a feature of PD.
- Ageing and PD Disconnect: Interestingly, the study did not find strong evidence of miRNAs being co-regulated in both Parkinson's Disease and general ageing processes, challenging a simple direct link in serum miRNA profiles.
- Network Analysis Reveals miRNA Communities: The network analysis highlighted that several differentially expressed miRNAs, including hsa-miR-144-3p, cluster together in specific communities within the dnPD cohort. This suggests coordinated biological functions among these miRNAs.
Key Results
- Differential Expression: hsa-miR-144-3p was consistently found to be significantly downregulated in drug-naïve PD patients compared to controls. This finding was robustly confirmed through both NGS and subsequent qPCR validation.
- Validation Cohort Results: The downregulation trend of hsa-miR-144-3p was also observed in advanced PD patients and in PD siblings (a population at higher genetic risk), although the magnitude of change varied.
- Other miRNAs: While hsa-miR-150-5p and hsa-miR-215-5p also showed differential expression in the discovery phase, their trends in the validation cohort were different from the initial findings, leading the researchers to focus exclusively on hsa-miR-144-3p. hsa-miR-122-5p was found to be specific to the CENT vs CTR contrast.
- Functional Annotation: Targets of hsa-miR-144-3p were enriched in pathways related to platelet function and coagulation.
Limitations and Future Work
- Limited Magnitude in Advanced Stages: While hsa-miR-144-3p showed a downregulation trend in adPD and PDsibs, the magnitude of this change was less pronounced than in dnPD. This suggests its role might be more prominent in the early stages or that other factors influence its levels later in the disease.
- Functional Details Unclear: The paper acknowledges that further research is needed to fully elucidate the precise functional mechanisms by which hsa-miR-144-3p influences coagulation and its specific role in PD pathogenesis.
- Ageing vs. PD Specificity: The lack of strong miRNA co-regulation between general ageing and PD in serum suggests that the observed changes in PD might be more disease-specific rather than solely age-driven. Future work could explore other biological compartments or more specific aging markers.
- Translational Potential: The authors suggest that hsa-miR-144-3p could be an early marker for PD, emphasizing the need for further research to validate its diagnostic and prognostic potential. Investigating its role in preventing or slowing disease progression is also a key future direction.
Summary updated